Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder

February 27, 2025
  • First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutions
  • Phase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity (neurogenic bladder) -related incontinence following spinal cord injury
  • First application worldwide of non-replicative herpes-based vectors in neuro-urology
  • Opens possibility of bringing genetic medicine to large disease populations in neurology

 

Read the full Press release in English or in French

< back

Recent posts

EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform development

read more >

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.